Blue Jet Healthcare Limited announced its financial results for the second quarter and first half of FY27. The company reported a quarterly revenue of INR376 crores and EBITDA of INR119 crores, marking a 28% increase in revenue and 21% in EBITDA sequentially. Key developments include the operationalization of its Hyderabad R&D center and progress in building its CDMO platform.
Blue Jet Healthcare Reports Strong Q2 FY27 Performance
Blue Jet Healthcare Limited has disclosed its financial and operational highlights for the second quarter and the first half of the fiscal year 2027, ending September 30, 2026. The company announced a significant increase in its quarterly performance, with revenues reaching INR376 crores and EBITDA at approximately INR119 crores. This represents a sequential growth of 28% in revenue and 21% in EBITDA compared to the previous quarter.
Key Financials and Growth Drivers
For the first half of FY27, Blue Jet Healthcare reported a revenue of INR669 crores, a 29% increase over H1 FY26. The Q2 FY27 revenue growth was primarily driven by the contrast media (25%) and PI API (52%) segments, partially offset by a degrowth in artificial sweetener (30%). Gross margin for Q2 stood at 49%, a decrease of 4% from the previous quarter, attributed to increased raw material prices due to the West Asia situation. However, the company anticipates a positive impact on gross margins in the coming quarters due to price increases being implemented.
Strategic Developments and Expansion
A major highlight for the quarter was the operationalization of the Hyderabad R&D center, which is expected to play a crucial role in strengthening developmental capabilities. The company is also advancing its long-term investment plans, including the development of its Vizag facility, which will support multiple chemistry technologies and customer programs. These efforts are geared towards building a differentiated, globally competitive CDMO platform and creating sustainable value for shareholders. The company also noted progress in its sustainability initiatives, with renewable energy contributing to about 80% of its overall consumption.
Operational Updates and Future Outlook
Mr. V.K. Singh, Chief Operating Officer, detailed the company’s manufacturing expansion plans, including the Mahad Unit 3 facility for contrast media and the phased development of the Vizag Unit 5 and Unit 6 for integrated pharmaceutical manufacturing. The company is focused on building a chemistry-led R&D platform and has seen progress in its development pipeline, including the successful delivery of a new contrast media intermediate. Looking ahead, Blue Jet Healthcare remains focused on sustaining momentum in existing businesses, translating its development pipeline into commercial opportunities, and executing expansion projects with discipline.
Source: BSE
